Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Users Online: 6041 | Home Print this page Email this page Small font size Default font size Increase font size
Year : 2012  |  Volume : 32  |  Issue : 5  |  Page : 93

PA01.43. In-vitro cyto chemical & flow-cytometry studies with las02- a coded herbo-mineral compound

Lavanya Ayurvedic Pvt. Ltd., Biotech Park, Lucknow, Pin- 226021, U.P., India

Correspondence Address:
Aditi Asthana
Lavanya Ayurvedic Pvt. Ltd., Biotech Park, Lucknow, Pin- 226021, U.P.
Login to access the Email id

Source of Support: None, Conflict of Interest: None

Rights and PermissionsRights and Permissions

Purpose: The drug optimization and understanding the mechanisms of action of drugs on the deregulation of cell cycle which is frequently considered as the cause of progression in cancer can provide important insights for new cancer treatment strategies. The drug LAS02 is a herbo mineral drug prepared as per ancient Ayurvedic literature. Method: In this study the effect of LAS02 was studied by analyzing the effect on cell cycle by flow cytometery on cancer cell lines breast cancer (MCF7), cervical cancer (HELA), colon cancer (COLO 205) and prostate cancer (DU 145), procured from NCCS, Pune. The cells were treated by different doses of LAS02, and assay for proliferation was performed by MTT assay test, subsequently, these were analyzed by flow cytometer for cell cycle analysis. Result: The results showed inhibition of proliferation in MCF7 by 77% and HELA cells by 78% at dose of 500μg/ml in MTT assay. In cell cycle analysis for COLO 205 treated with LAS02, the percentage retention of the cells in G0/ G1 phase was 73.07% at 300μg/ml as compared to 52.16% in the control after 24hrs. In DU 145, treated with LAS02, cells that retained at G0/G1 phase were 79.28% at a dose of 400μg/ml after 48hrs; as compared to control of 62.41%. The apoptosis observed at 400μg/ml drug concentration was 43.51%. Conclusion: The study shows that LAS02 acts as a potent anti cancerous compound by inhibiting proliferation as well as by inducing retention of cells in G0/G1 phase along with apoptosis significantly at in vitro level. Therefore, LAS02 arrests the cancerous cells in G0/G1 phase and prevented the entry of pre cancerous stem cells from G0/G1 phase into G2, the subsequent proliferative stage and inhibits cancer cells from completing the cell cycle. Such a finding is unique with this new drug, which holds a great promise as one of the most effective and safest cancerostatic drug.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded53    
    Comments [Add]    

Recommend this journal